Patents by Inventor Birgitte Ursø

Birgitte Ursø has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-IL-22R ANTIBODIES
    Publication number: 20230088269
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.
    Type: Application
    Filed: August 11, 2022
    Publication date: March 23, 2023
    Inventors: Christophe Frederic Jerome BLANCHETOT, Birgitte URSØ, Tine SKAK-NIELSEN, Malene BERTELSEN, Sebastian VAN DER WONING, Michael SAUNDERS, Johannes Joseph Wilhelmus DE HAARD
  • IL-1 Receptor Accessory Protein Inhibitors and Uses Thereof
    Publication number: 20220411517
    Abstract: The present disclosure provides novel antibodies and fragments thereof targeting IL-1RAcP. Use of IL-1RAcP inhibitors are also provided herein.
    Type: Application
    Filed: May 20, 2022
    Publication date: December 29, 2022
    Inventors: Birgitte Ursø, Waseem Sajid, Paola Lovato, Heidi Westh Bagger, Christoph Erkel, Petra Nussbaumer, Simon Schuster
  • Anti-IL-22R antibodies
    Patent number: 11447544
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: September 20, 2022
    Assignee: argenx BV
    Inventors: Christophe Frederic Jerome Blanchetot, Birgitte Ursø, Tine Skak-Nielsen, Malene Bertelsen, Sebastian Van Der Woning, Michael Saunders, Johannes Joseph Wilhelmus De Haard
  • Anti-IL-22R antibodies
    Patent number: 11261246
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: March 1, 2022
    Assignee: argenx BV
    Inventors: Christophe Frederic Jerome Blanchetot, Birgitte Ursø, Tine Skak-Nielsen, Malene Bertelsen, Sebastian Van Der Woning, Michael Saunders, Johannes Joseph Wilhelmus De Haard
  • ANTI-IL-22R ANTIBODIES
    Publication number: 20200216528
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.
    Type: Application
    Filed: October 23, 2019
    Publication date: July 9, 2020
    Inventors: Christophe Frederic Jerome BLANCHETOT, Birgitte URSØ, Tine SKAK-NIELSEN, Malene BERTELSEN, Sebastian VAN DER WONING, Michael SAUNDERS, Johannes Joseph Wilhelmus DE HAARD
  • Anti-IL-22R antibodies
    Patent number: 10696741
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: June 30, 2020
    Assignee: argenx BVBA
    Inventors: Christophe Frederic Jerome Blanchetot, Birgitte Ursø, Tine Skak-Nielsen, Malene Bertelsen, Sebastian Van Der Woning, Michael Saunders, Johannes Joseph Wilhelmus De Haard
  • ANTI-IL-22R ANTIBODIES
    Publication number: 20200157207
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.
    Type: Application
    Filed: October 23, 2019
    Publication date: May 21, 2020
    Inventors: Christophe Frederic Jerome BLANCHETOT, Birgitte URSØ, Tine SKAK-NIELSEN, Malene BERTELSEN, Sebastian VAN DER WONING, Michael SAUNDERS, Johannes Joseph Wilhelmus DE HAARD
  • ANTI-IL-22R ANTIBODIES
    Publication number: 20190127459
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.
    Type: Application
    Filed: January 8, 2019
    Publication date: May 2, 2019
    Inventors: Christophe Frederic Jerome BLANCHETOT, Birgitte URSØ, Tine SKAK-NIELSEN, Malene BERTELSEN, Sebastian VAN DER WONING, Michael SAUNDERS, Johannes Joseph Wilhelmus DE HAARD
  • Antibodies against human NKG2D and uses thereof
    Patent number: 7879985
    Abstract: The present invention provides isolated anti-human NKG2D monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the risk for immune responses against the antibodies when administered to a patient. Preferred antibodies include human monoclonal antibodies MS and 21F2. As described herein, other antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules, can be designed or derived from such antibodies.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: February 1, 2011
    Assignee: Novo Nordisk A/S
    Inventors: Birgitte Ursø, Peter Andreas Nicolai Reumert Wagtmann, Inger Lund Pedersen
  • Antibodies against human NKG2D and uses thereof
    Publication number: 20100056764
    Abstract: The present invention provides isolated anti-human NKG2D monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the risk for immune responses against the antibodies when administered to a patient. Preferred antibodies include human monoclonal antibodies MS and 21F2. As described herein, other antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules, can be designed or derived from such antibodies.
    Type: Application
    Filed: October 23, 2009
    Publication date: March 4, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Birgitte Ursø, Peter Andreas Nicolai Reumert Wagtmann, Inger Lund Pedersen, Anders Svensson